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Abstract
Background: Osteoporosis incidence in children is increasing due to the increased survival rate of patients
suffering from chronic diseases and the increased use of drugs that can damage bones.
Recent changes made to the definition of childhood osteoporosis, along with the lack of guidelines or national
consensuses regarding its diagnosis and treatment, have resulted in a wide variability in the approaches used to
treat this disease.
For these reasons, the Osteogenesis Imperfecta and Childhood Osteoporosis Working Group of the Spanish Society
of Pediatric Rheumatology has sounded the need for developing guidelines to standardize clinical practice with
regard to this pathology.
Methods: An expert panel comprised of 6 pediatricians and 5 rheumatologists carried out a qualitative literature
review and provided recommendations based on evidence, when that was available, or on their own experience.
The level of evidence was determined for each section using the Oxford Centre for Evidence-based Medicine
(CEBM) system. A Delphi survey was conducted for those recommendations with an evidence level of IV or V. This
survey was sent to all members of the SERPE. All recommendations that had a level of agreement higher or equal
to 70% were included.
Results: Fifty-one recommendations, categorized into eight sections, were obtained. Twenty-four of them
presented an evidence level 4 or 5, and therefore a Delphi survey was conducted. This was submitted electronically
and received a response rate of 40%. All recommendations submitted to the Delphi round obtained a level of
agreement of 70% or higher and were therefore accepted.
Conclusion: In summary, we present herein guidelines for the prevention, diagnosis and treatment of secondary
childhood osteoporosis based on the available evidence and expert clinical experience. We believe it can serve as a
useful tool that will contribute to the standardization of clinical practice for this pathology. Prophylactic measures,
early diagnosis and a proper therapeutic approach are essential to improving bone health, not only in children and
adolescents, but also in the adults they will become in the future.
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Background
Osteoporosis is a disorder characterized by bone mass
reduction and alterations in the micro-architecture of
the bone tissue resulting in bone fragility and, conse-
quently, an elevated risk of fractures [1]. At present,
osteoporosis is a public health problem in industrialized
countries affecting about 30% of women and 8% of men
older than 50 in Europe [2]. Although it has typically been
considered an adult disorder, it is becoming increasingly
clear that osteoporosis might be rooted in childhood and
adolescence [3]. Bone matrix mineralization takes place
during these stages of life, and therefore subjects reach peak
bone mass at the end of this growth phase. If this peak is
not optimal, it will facilitate the development of osteopor-
osis in adulthood [3].
Furthermore, the incidence of childhood osteoporosis is
increasing due to, among other factors, the increased sur-
vival rate of patients suffering from chronic diseases and
the increased use of drugs that can damage bones [4].
In its Official Positions published in 2013, the Inter-
national Society for Clinical Densitometry considered
two possible conditions regarding the diagnosis of child-
hood osteoporosis [5]:
– Presence of one or more vertebral fractures (VF)
in the absence of local disease or high-energy
trauma.
– Z-score of bone mineral density (BMD) or bone
mineral content (BMC) ≤ − 2 (adjusted for size in
cases of children measuring below the 3rd
percentile) and a history of clinically significant
fractures; specifically:
 two or more long bone fractures occurring by age
10 years; or
 three or more long bone fractures at any age up
to age 19 years.
Moreover, their guidelines state that a Z-score higher
than -2 does not preclude the possibility of bone fragil-
ity, especially in those patients suffering from disorders
that favor secondary osteoporosis.
At present, in pediatrics there is growing interest
in this pathology. However, recent changes made to
the definition of childhood osteoporosis [5, 6], along
with the lack of guidelines or national consensuses
regarding its diagnosis and treatment, have resulted
in a wide variability in the approaches used to treat
this disease [7].
For these reasons, the Working Group of Osteogenesis
Imperfecta and Childhood Osteoporosis of the Spanish
Society of Pediatric Rheumatology (SERPE, by its Span-
ish acronym) has sounded the need for developing
guidelines to standardize clinical practice with regard to
this pathology.
Methods
Design
A qualitative synthesis of scientific evidence and consen-
sus based on clinical experience and existing scientific
evidence was used to formulate the study design.
Development stages
Preparation began with the establishment of an expert
panel comprised of 11 physicians, 6 pediatricians and 5
rheumatologists. All are members of the SERPE and
have experience in the diagnosis and treatment of sec-
ondary osteoporosis in children.
Study coordination was undertaken by one of the
physicians.
This panel of experts reached a consensus on the es-
sential contents to include in the document, consisting
of the following eight sections:
1. When osteoporosis should be suspected
2. How to prevent it
3. Laboratory tests used in screening
4. Imaging tests used in screening
5. Treatment: calcium and vitamin D supplementation
6. Treatment: bisphosphonates (BPs)
7. Follow-up
8. Glucocorticoid-induced osteoporosis (GIOP)
One or two experts were appointed to be responsible
for a literature review of each section, which was con-
ducted with the assistance of a rheumatologist and an
expert in methodology.
Following the revision, each of the experts responsible
for the literature review provided recommendations re-
garding each section based on evidence, when that was
available, or on their own experience.
Afterwards, the panelists held a meeting to discuss and
draft the recommendations. The level of evidence was de-
termined for each section using the Oxford Centre for
Evidence-based Medicine (CEBM) system. For this pur-
pose, both a rheumatologist and an expert in methodology
provided guidance. A Delphi survey was conducted for
those recommendations with an evidence level of IV or V.
This survey was sent to all members of the SERPE. All
recommendations that had a level of agreement higher or
equal to 70% were included.
Results
A total of 51 recommendations, categorized into eight sec-
tions, were obtained (Table 1). Twenty-four of them pre-
sented an evidence level 4 or 5, and therefore a Delphi
survey was conducted. This was submitted electronically
and received a response rate of 40%. All recommendations
submitted to the Delphi round obtained a level of agree-
ment of 70% or higher and were therefore accepted.
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Table 1 Recommendations, levels of evidence, grade of recommendation according to the Oxford CEBM and level of agreement in
Delphi round*
Recommendation LE GR LADR
General recommendations
1 There is a need to monitor BMD in patients with chronic diseases, especially those of endocrinologic, nutritional,
rheumatological, renal, metabolic, hematological, neurological and gastrointestinal origin. There is no universal consensus
regarding when and how to carry out such an assessment for all the pathologies involved. Following the existing
guidelines for each pathology is therefore recommended [8–22].
4 D 95%
2 Special attention must be paid to patients with chronic diseases who receive treatments that contribute to osteoporosis
development; e.g., GCs, chemotherapy treatments or antiepileptic drugs [17, 19, 20, 23–28].
2b B
Lifestyle and dietary habits
3 It is important to identify those children at risk for osteoporosis due to causes related to lifestyle, long-term immobilization
or problems of anorexia or malnutrition [19, 29–34].
2a B
4 Healthy dietary habits must be established by means of a balanced diet that meets specific calcium and vitamin D
requirements for each age and allowing for adequate nutritional intake [35, 36].
2a B
5 Tobacco, caffeine and alcohol use must be avoided in children and adolescents [35, 37, 38] [39–41]. 2a B
6 High impact and low frequency exercise - e.g., running or jumping - must be recommended for healthy children and
adolescents [31, 42–46].
1a A
7 This kind of sport must also be recommended for children with low BMD [23, 47, 48]. 3a C
8 It is important to recommend exposure to sunlight on the hands, face and arms between six to eight minutes/day in the
summer (avoiding the hottest part of the day between 10 a.m. and 3 p.m.) and 30 min/day during the coldest months of
the year [15, 49, 50].
4 D 90%
Complementary test
9 Children with chronic diseases are at greater risk of vitamin D deficiency than the general
population. Therefore, it would be advisable to monitor them, mostly during the end of winter [49–51].
2a B
10 Regarding all children and adolescents who are suspected of suffering from secondary osteoporosis, the following lab work
for the initial study is recommended: blood and urine chemistry, urine screening and bone turnover markers (Table 6) [52].
5 D 83%
11 The role of bone turnover makers in pediatric populations with bone fragility is insufficiently defined, but they can be useful
in treatment follow-up and evaluation. For this reason, they are included in the initial study of these patients [23, 52–56].
5 D 80%
12 Measurements of bone turnover makers in urine are not recommended for all patients since the collection of the sample
may be not correctly carried out due to the patient’s age or concomitant disease [57].
5 D 90%
13 Specific complementary tests detailed in Table 7 can be carried out for some children and adolescents depending on the
suspected underlying condition [15, 23, 58].
5 D 90%
14 Interpretation of analytical values must be done taking into consideration the factors that modify them. These factors are
biological (age, sex, pubertal stage, ethnicity) and other controllable variables (circadian rhythm, diet, season of the year)
[53, 55–61].
2b B
15 Since low bone mass has been associated with increased fracture risk, DXA is the most recommended method for pediatric
populations in order to assess bone health. However, it does not allow for a prediction of fracture risk [34, 48, 62, 63].
2a B
16 DXA of the lumbar spine and total body less head (TBLH) is the chosen method to measure BMD in pediatric populations,
since they are the most accurate and reproducible areas of the skeletal system for this measurement [6, 64, 65].
2a B
17 Data analyses must be carried out using pediatric software (software for adults overestimates BMD) [66, 67]. 2b B
18 Vertebrae DXA measurement is recommended for children under the age of five due to its higher reproducibility and
shorter time necessary for conducting this test [5, 6, 64, 66, 67].
2a B
19 For children under the age of three, total body BMD is not recommended on a routine basis due to its lack of
reproducibility in such young children; rather BMC should be used [5, 6, 64].
3a C
20 Regarding children of short stature (< p3) or with a growth retardation problem, it is recommended to adjust their results
by means of a size Z-score [6, 23, 64, 68, 69].
2a B
21 For children suffering from joint contracture or with mobility problems - e.g., with cerebral palsy - distal femur
measurement can be an alternative [68].
2a B
22 For children with suspected secondary osteoporosis, it is recommended to extend the study with a plain lateral thoracic
and lumbar X-ray to assess vertebral compression fractures, particularly if they are receiving GCs [23, 70–73].
2b B
23 In the event of low bone mass or risk factor persistence, a second plain lateral thoracic and lumbar X-ray should be taken
after one year [70, 71] .
3b C
24 The minimum time interval to wait before repeating a bone density measurement is six months, a period of one year being
advisable, apart from exceptional cases [6, 64, 66, 74, 75].
3b C
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Table 1 Recommendations, levels of evidence, grade of recommendation according to the Oxford CEBM and level of agreement in
Delphi round* (Continued)
Recommendation LE GR LADR
25 DXA can be used to assess treatment response after six months in the event of high doses of corticosteroids,
chemotherapy, or in situations of malnutrition or active treatment [6, 64, 66, 74].
3b C
26 In cases of children who initially present normal densitometry results, but in whom risk factor(s) persist, the periodicity of
the densitometry must be individualized according to the risk factor associated and an interval of one or two years is
advised until peak bone mass is reached [6, 64, 66, 74, 75].
5 D 95%
Prevention
27 Oral calcium supplementation could improve BMD in healthy children with a low-calcium diet. Nevertheless, increasing cal-
cium intake by means of calcium-rich foods is preferable to supplementation [36–38, 76].
5 D 90%
28 With respect to children with chronic diseases, adequate treatment of the disease is the most important step to be taken
regarding osteoporosis prevention and treatment [23, 77–79].
2b B
Treatment
29 Vitamin D supplementation must be prescribed for all those patients with chronic pathologies presenting levels lower than
20 ng/mL and for those with levels between 20-30 ng/mL who present Z-score≤ − 2 or any data showing bone fragility [51,
80, 81].
4 D 90%
30 For children and adolescents with a low BMD or osteoporosis, calcium supplementation is recommended, particularly for
those patients with a low-calcium diet, as well as supplementation of the proper amount of vitamin D3 in order to keep
plasmatic levels of 25-hydroxyvitamin D3 higher than 30 ng/dL [82, 83].
2b B-C
31 The required amount of calcium and vitamin D supply needed in children with pathologies that can jeopardize intestinal
absorption or modify their body’s use of these nutrients is unknown. For this reason, in the event that such patients present
osteoporosis or low BMD according to chronological age, it is advisable to initially prescribe the dose required to ensure a
recommended daily intake of healthy children. Treatment can be modified according to plasmatic 25-hydroxyvitamin D3,
iPTH and calciuria levels, which must be monitored every six to twelve months [49–51, 82, 83].
5 D 90%
32 Treatment with BP should be administered to those pediatric patients with osteoporosis (Z-score≤ − 2 + pathological
fracture or VF regardless of Z-score) [9, 84–88].
1b A
33 Treatment with BP can be considered for patients without osteoporosis, but a low BMD in early puberty (Tanner 2):
- When active risk factors are present: patients with Z ≤ − 2. 5 SD (with a declining trajectory confirmed at least on two
separate occasions with one year apart).
- When patients no longer present active risk factors: patients with Z ≤ -3DS (with a declining trajectory confirmed on at
least on two separate occasions with one year apart) [9, 84–87].
5 D 78%
34 Intravenous BPs should be used whenever there are VF, if there is some contraindication to the use of oral BPs, or
according to the patient’s preferences [88–91].
3a B-C
35 Oral BPs can be used in the absence of contraindications and VF, or during the de-escalation phase [9, 84–87]. 5 D 70%
36 The BP dosage should be discontinued or progressively reduced in those patients not presenting fractures during the
preceding year and having reached a Z-score higher than -2 [9, 84–87].
5 D 90%
Follow-up
37 A follow-up is recommended for patients at risk for osteoporosis while other risk factors persist and during treatment with
calcium and/or vitamin D3, BPs or other osteoporosis treatments [49, 51, 74].
4 D 95%
38 Calcium and phosphorus metabolism (serum levels of calcium, phosphorus, alkaline phosphatase, iPTH and 25-
hydroxyvitamin D3) should be evaluated on an annual basis [49, 51].
4 D 90%
39 During treatment with vitamin D, it is recommended to monitor serum levels of 25-hydroxyvitamin D3 every 6 to 12
months, unless the dosage is changed. In such cases, patients should be monitored at 3–6 months [49, 51].
5 D 88%
40 During supplementation with calcium and/or vitamin D3, calcium/creatinine levels in urine should be monitored at least
once a year. Renal ultrasounds should be conducted to rule out nephrocalcinosis in the event of calciuria increase, or when
it is not possible to determine calciuria due to the patient’s age or pathology [49–51, 82, 83].
5 D 83%
41 DXA is recommended one year after the baseline DXA, and then subsequently every 1 or 2 years depending on the
trajectory observed. The minimum interval should be 6–12 months [74].
4 D 93%
42 It is recommended to perform simple lateral thoracic and lumbar X-rays to assess VF every 6 months to 2 years (with 1 year
being the average), according to the risk factor magnitude and the functional status of the child [51, 71, 74].
5 D 73%
43 For pediatric patients with reduced mobility due to cerebral palsy and congenital myopathies, a spine X-ray is recom-
mended at 6–8 years of age, or earlier in the event of back pain, and then periodically until the end of growth [23].
5 D 88%
44 During treatment with intravenous BPs, assessments of laboratory parameters are recommended before each
administration. For oral BPs, checks every six months are recommended [9, 84–86, 88–92].
5 D 83%
45 During treatment with BPs, annual DXA is recommended [9, 84–86, 88–92]. 5 D 85%
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Discussion
When osteoporosis should be suspected
Factors that contribute to osteoporosis in children and
adolescents can be both genetic and lifestyle associated.
In children suffering from chronic diseases or receiv-
ing bone harmful treatments for a prolonged period of
time, several factors that increase bone resorption and
decrease bone formation converge and result in in-
creased bone fragility [100] [63]. For this reason, bone
health must be assessed during follow-up, adopting ad-
equate preventive measures.
Table 2 shows some of the pathologies responsible for
secondary osteoporosis.
There is no universal consensus regarding when and
how to assess bone health for all of the pathologies in-
volved. However, there are some clinical guidelines for
different pediatric disorders (Table 3).
BMD in patients with chronic diseases should be moni-
tored based on the existing guidelines for each disorder.
In addition, special attention must be paid to patients suf-
fering from chronic diseases and receiving treatment that
may favor the development of osteoporosis; e.g., glucocor-
ticoids (GCs), chemotherapy or antiepileptic drugs.
How to prevent osteoporosis
There are numerous factors that impact bone health in
children. Many of these are modifiable, at least in part
(Table 4) [35].
Nutritional factors with higher evidence of conferring
a positive effect on bone health are calcium, phosphorus
and vitamin D [23]. Table 5 shows the daily nutrient re-
quirements for a healthy child [103], although children
suffering from chronic diseases or under treatment with
drugs that alter intestinal absorption may need higher
intakes of calcium and vitamin D [23, 35, 49, 104].
Calcium-rich foods are preferable to supplements for
attaining optimal calcium intake, not only because they
have a higher bioavailability [23] and are easier to digest,
but also because their consumption avoids possible sec-
ondary cardiovascular effects common in adults [105]
and favors positive nutritional habits from childhood
[23]. Thus, systematic supplementation with calcium in
the absence of osteoporosis or low BMD is not recom-
mended [106]. It should only be considered for those pa-
tients with calcium-poor diets [42].
Vitamin D is an important hormone for the absorp-
tion and use of calcium [103]. There is some dispute
regarding the optimal levels of vitamin D, although in
general terms, serum levels of 25-hydroxyvitamin
D3 ≥ 50 nmol/L (20 ng/mL) are considered normal.
Those between 30-50 nmol/L (12-20 ng/mL) are regarded as
insufficient, and those < 30 nmol/L (12 ng/mL) deficient [49].
In order to maintain appropriate levels, the intake of
food enriched in vitamin D is important, as well as daily
exposure to sunlight on the hands, face and arms for 6
to 8 min in the summer months (avoiding the hottest
part of the day) and 30min in the coldest months of the
year. However, there is no exposure to ultraviolet B
(UVB) rays that is safe in terms of skin cancer [49].
Children suffering from chronic diseases have an in-
creased risk of vitamin D deficiency. Therefore, monitor-
ing vitamin D serum levels would be advisable in these
patients, especially in late winter [104].
In addition, a large number of other nutrients play a
significant role in bone metabolism, such as proteins,
potassium, magnesium, copper, iron, phosphate, zinc
and vitamin A, C and K [23, 104]. Thus, it is important
Table 1 Recommendations, levels of evidence, grade of recommendation according to the Oxford CEBM and level of agreement in
Delphi round* (Continued)
Recommendation LE GR LADR
Corticosteroid-induced osteoporosis
46 Lateral spine x-ray is recommended in order to detect VF at the beginning of treatment
with GCs and after one year [70, 71, 93].
2a B
47 It is recommended to carry out lumbar spine or TBLH DXA within the first six months after the beginning of treatment with
GCs, and then every 9 to 12 months if treatment continues [94].
4 D 85%
48 It is recommended to start simultaneous treatment and/ or optimize calcium intake (500–1000mg/day) and vitamin D 400
IU/day for those patients who are scheduled to receive systemic GCs for three months or more [95].
2b B
49 Treatment with calcium and vitamin D must be maintained for three months after discontinuation of GCs [95]. 5 D 88%
50 For children and adolescents receiving GCs chronically and presenting low BMD (Z-score≤ − 2) and pathological fractures, it
is recommended to use BPs associated with calcium and vitamin D [87, 95, 96].
1b A
51 Lateral spine x-rays or BMD checks with DXA are not recommended on a routine basis for those children and adolescents
being treated with inhaled GCs at dosages under 800 mcg/day, unless they present other risk factors [97–99].
1b A
LE level of evidence, GR grade of recommendation, LADR Level of agreement in Delphi round, GCs glucocorticoids, BMD bone mineral density, BMC bone mineral
content, DXA dual-energy x-ray absorptiometry, iPTH intact parathyroid hormone, BPs bisphosphonates, VF vertebral fractures
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to recommend a varied diet, including fruits and vegeta-
bles, to ensure an adequate intake of key nutrients in
order to maintain good bone health in children and ado-
lescents [23, 35, 104].
Moreover, exercise and regular physical activity are
considered among the most effective strategies for maxi-
mizing peak bone mass during childhood [23, 35, 42,
104]. High impact and low frequency exercise - e.g.,
jumping, running or resistance training - favor BMD in-
crease in children and are more suitable than others
such as swimming or biking in terms of bone health [35,
43, 104]. Nevertheless, physical activity with excessive
impact increases fracture risk [44].
There are other factors such as tobacco, caffeine and
alcohol consumption that are associated with decreased
BMD and increased fracture risk [35, 37, 38, 104]. This
is one reason, among others, to avoid their consumption
in children and adolescents.
It is also essential to maintain an adequate nutritional
state because both, extreme thinness and adiposity, are
associated with lower BMD and increased fracture risk
[29, 30, 35].
Furthermore, the optimal control of the primary dis-
ease is the most effective way to prevent and treat sec-
ondary osteoporosis [23, 35].
Diagnosis
Laboratory tests
The diagnosis of secondary osteoporosis is usually made
after the diagnosis of the underlying disease that causes
it. However, in some cases, it may be the first manifest-
ation of the underlying disease. Although most of the
disorders included in the differential diagnosis can be in-
ferred by means of a thorough medical history review
and physical examination, some pathologies - e.g., phos-
phocalcic metabolism alterations, hypothyroidism or
some types of leukemia- can be paucisymptomatic and
require complementary tests for accurate diagnosis
[100]. For this reason, it is recommended to perform the
analytical parameters listed in Table 6 when assessing a
child with suspected or established diagnosis of secondary
osteoporosis. Regarding the parameters shown in Table 7,
they are only justified in the event of clinical suspicion.
These biochemical parameters must be interpreted
based on factors such as age, sex, growth rate, nutri-
tional status and pubertal stage, among others [52, 59].
Bone turnover markers are certain substances released
into the bloodstream during bone formation or resorp-
tion that reflect bone metabolic activity at a given time.
Though numerous, amino-terminal propeptides from
type 1 procollagen (P1NP) and carboxy-terminal telo-
peptides (CTx) should be used as reference markers to
evaluate formation and resorption, respectively [107,
108]. These can be measured in the blood and urine
[109], although for children it is preferable to determine
them in plasma [53, 110, 111]. In adults, they have been
shown to be useful for monitoring treatment in patients
with osteoporosis [112]. In children, however, such inter-
pretation is much more complex [54, 110, 113], although
they can help in monitoring antiresorptive therapy com-
pliance and measuring its effectiveness [100].
Imaging tests
The diagnosis of childhood osteoporosis is essentially
based on the presence of fragility fractures. However, a
Table 2 Causes of secondary osteoporosis
Neuromuscular disorders Cerebral palsy
Duchenne muscular dystrophy
Rett syndrome
Myopathies
Diseases resulting in long-term
immobilization
Hematological diseases Leukemias
Hemophilia
Thalassemia
Systemic autoimmune
diseases
Juvenile systemic lupus erythematosus
Juvenile dermatomyositis
Systemic juvenile idiopathic arthritis
Systemic sclerosis
Lung diseases Cystic fibrosis
Gastrointestinal diseases Celiac disease
Inflammatory bowel disease
Chronic liver disease
Cow’s milk protein allergy
Renal diseases Nephrotic Syndrome
Chronic renal failure
Psychiatric illnesses Anorexia nervosa
Infectious diseases HIV infection
Immunodeficiencies
Endocrine diseases Delayed puberty
Hypogonadism
Turner syndrome
Klinefelter Syndrome
Growth hormone deficiency
Acromegaly
Hyperthyroidism
Diabetes
Hyperprolactinemia
Cushing syndrome
Adrenal insufficiency
Hyperparathyroidism
Vitamin D metabolism disorders
Inborn errors of metabolism Glycogen storage disease
Galactosemia
Gaucher disease
Skin conditions Epidermolysis bullosa
Iatrogenesis Systemic glucocorticoids
Cyclosporine
Methotrexate
Heparin
Anticonvulsants
Radiation therapy
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dual-energy x-ray absorptiometry (DXA) is recommended
to ensure a complete assessment of bone health [5].
Despite numerous limitations [100], DXA is the
chosen method for determining bone health in children.
Lumbar spine and total-body less head are the preferred
skeletal sites for performing DXA as they are the most
accurate and reproducible areas in children. In addition,
Z-score should be adjusted according to the height in
children with a size below the 3rd percentile [5].
Other techniques for assessing bone quality in pediatrics
are peripheral quantitative computed tomography and
ultrasound. However, although superior to DXA in certain
aspects, there are insufficient studies of pediatric popula-
tions to recommend their use on a routine basis [100].
Furthermore, in a patient with suspected or confirmed
bone fragility, the presence of VF, which are frequently
asymptomatic, should always be assessed by means of a
simple lateral full spine x-ray or by DXA vertebral frac-
ture assessment, if feasible [39, 114].
Treatment
Calcium and vitamin D supplementation
Calcium and vitamin D supplementation have not
shown any clinically significant effect on BMD in studies
performed in healthy children [106]. In contrast, some
studies have reported a favorable effect in patients with
chronic diseases that favor osteoporosis such as cerebral
palsy [8]. On the other hand, no side effects have been
reported [8, 40]. Thus, although there are no studies that
assess the effect of supplementation on the incidence of
fractures, calcium supplementation is considered
Table 3 Assessment of BMD for certain diseases or chronic treatments involved in childhood secondary osteoporosis
Disease / Treatment BMD assessment
Celiac disease DXA if:
-no adequate dietary adherence
-irregular menstruation
-anemia
-other risk factors for fractures [74]
Cerebral palsy Difficult lumbar spine X-ray interpretation in cases of severe scoliosis.
Total-body or distal femur DXA (area with higher fracture risk), only if there are fragility fractures [8].
Duchenne muscular
dystrophy
Baseline DXA and annual monitoring.
Lateral spine x-ray: Baseline
- On GCs treatment: Repeat every 1–2 years.
- Not on GCs treatment: Repeat every 2–3 years.
- If back pain or ≥ 0, 5 SD decline in spine BMD Z score on serial measurements over 12-month period: Repeat.
Refer to osteoporosis specialist following the first fracture [11].
Rett syndrome Baseline DXA, and serial controls according to individual risk [15].
Epilepsy Consider DXA for epileptic patients receiving anti-epileptic drugs for a prolonged period [13]
Thalassemia DXA every 2 years from adolescence [12]
Inflammatory/ systemic
disease
Consider DXA for patients receiving high doses of GCs [74].
Juvenile idiopathic
arthritis (JIA)
< 6 years: DXA in the presence of fragility fractures.
> 6 years: DXA if not presenting rapid remission of JIA or in need of high doses of GCs [18].
Neoplasms Baseline DXA two years after completing chemotherapy with osteotoxic drugs; e.g., MTX, GCs or hematopoietic cells
transplantation; or secondary effects that favor osteoporosis development (growth hormone deficiency, hypogonadism,
etc.)
DXA follow-up based on the results of baseline DXA and persistent risk factors [17]
Cystic fibrosis DXA in children ≥ age 8 if:
- weight < 90% ideal weight
- FEV1 < 50%
- Delayed puberty
- High dosis of GCs > 90 days per year
At 18, all of them [101].
Diabetes mellitus DXA if:
- low BMD specific risk factors
- increased daily insulin dosis
- impaired renal function
- fracture history [74]
Anorexia nervosa DXA in patients with amenorrhea for more than 6 months [13].
Systemic lupus
erythematosus
DXA evaluation in patients with prolonged systemic GCs exposure exceeding ≥0.15 mg/kg daily for ≥ 3 months. Repeat
on an annual basis if Z-score≤ − 2 [102].
DXA dual-energy x-ray absorptiometry, BMD bone mineral density, GCs glucocorticoids, MTX methotrexate, FR risk factors
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advisable in children and adolescents with low BMD or
osteoporosis, especially those patients with a low
dietary intake.
Likewise, ensuring proper vitamin D3 intake is recom-
mended in order to maintain plasmatic levels of 25-
hydroxyvitamin D3 higher than 50 nmol/l (20 ng/dL).
Table 6 shows the recommended daily intake of calcium
and vitamin D for healthy children [103]. The optimal in-
take for children with disorders that may interfere with in-
testinal absorption or modify calcium metabolism remains
unknown [41]. Thus, initially, supplementation should be
prescribed with respect to these recommendations and
subsequently be modified according to plasmatic 25-
hydroxyvitamin D3, intact paratohormone (iPTH) and cal-
ciuria, which must be monitored every 6–12months.
Bisphosphonates
BPs are synthetic analogs of pyrophosphate that inhibit
bone resorption. They selectively concentrate and in-
crease BMD in high remodeling rates skeleton areas
[115]. They are hydrophilic drugs with low intestinal ab-
sorption (< 1%) and high distribution volumes that are
excreted in urine. Thus, dosages must be adjusted ac-
cording to glomerular filtrate. Moreover, they are char-
acterized by a very slow elimination from bone tissue,
and remain in the body for years after treatment [115].
Knowledge on the mid- and long-term safety of these
drugs is constantly increasing [100]. Thus, some authors
recommend their use as long as osteoporotic criteria are
met, particularly in those patients with long bones and VF
and who exhibit poor potential for spontaneous recovery
(age at puberty, risk factor persistence, etc.) [116].
To date, BPs have only been prescribed as a secondary
prevention measure. In other words, once the first frac-
ture occurs. Their use is intended to prevent the appear-
ance of new fragility fractures. It is currently known that
they confer a positive effect on BMD [9, 84–87], and
there is increasing knowledge regarding their long-term
safety [100]. On the other hand, if the peak bone mass
reached at the end of the growth stage is not optimal,
osteoporosis is more likely to develop during the later
stages of life [3]. On the basis of the above data, our
working group recommends that clinicians consider
treatment with BPs for those patients without osteopor-
osis, but low BMD in early puberty, with low Z-scores
and decreasing trajectories.
In any case, BPs are used off label in childhood osteo-
porosis, so informed consent must be obtained when
they are prescribed.
Second and third generation BPs are the most com-
monly used BPs in children. Some of them are intraven-
ously administered and others orally [100]. Oral BPs are
widely used in adulthood osteoporosis, and some studies
have demonstrated that they increase BMD and decrease
fracture risk in patients with Osteogenesis Imperfecta.
Nevertheless, in contrast to intravenous BPs, they
lack sufficient potency to induce remodeling after VF
[117] and are contraindicated in patients with
esophagitis risk factor; e.g., gastroesophageal reflux
or hiatal hernia. Intravenous BPs are preferred for
pediatric osteoporosis, and oral BPs are only used
for patients with mild forms of osteoporosis, without
VF, when intravenous administration is contraindi-
cated for any reason, or during the treatment main-
tenance phase [100].
Table 8 shows doses and dosing intervals for the most
commonly used BPs in pediatrics [100].
The optimal treatment duration is not clearly defined
and is currently based on expert recommendations
[116]. We propose discontinuing or progressively
Table 4 Risk factors of osteoporosis in childhood
Modifiable Nutritional • Caloric intake
• Protein intake
• Calcium intake
• Phosphorus intake
• Vitamin D
• Others (vitamins K, group B, Mg, K
…)
Lifestyle • Solar exposure
• Physical exercise
• Tobacco
• Alcohol
Partly
modifiable
High risk
diseases
• Prematurity
• Pregnancy and nursing in
adolescents
• Intestinal malabsorption
• Cystic fibrosis
• Celiac disease
• Inflammatory bowel disease
• Food allergies
• Chronic lactose intolerance
• Chronic liver disease
• Chronic kidney disease
• Cerebral palsy
• Chronic rheumatic diseases …
Hormonal • Treatment with glucocorticoids
• Hyperparathyroidism
• Hypogonadism
Non-
modifiable
Genetics
Sex
Ethnicity
Table 5 Daily calcium and vitamin D requirements according to
age
Age Calcium (mg) Vitamin D (IU)
0–6 months 200 400
6–12months 260 400
1–3 years 700 600
4–8 years 1000 600
9-18 years 1300 600
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decreasing BPs dosing for those patients who have not
presented fractures during the preceding year and who
have attained a Z-score higher than -2.
Follow-up
The aim of follow-up in patients with osteoporosis risk
factors is to identify those candidates who need to start or
maintain specific treatments. For such patients and those
with an established osteoporosis diagnosis, follow-up
should be continued as long as risk factors persist or while
treatment is maintained with calcium and/or vitamin D3,
BPs or other medications for osteoporosis [49, 51, 74].
Clinical, radiological and analytical parameters should
be monitored. Assessing the number of fragility fractures
and pain episodes is important. In terms of densitom-
etry, variations in Z-scores are relevant. The optimal fre-
quency for DXA performance is insufficiently defined
[74]. Our recommendation is to repeat DXA after one
year, and then every 1–2 year thereafter according to the
patient’s trajectory, with a minimum interval between
checks of 6–12 months.
It is also crucial to perform a radiological assessment
of VF, since they are frequently asymptomatic and can
appear even in patients with Z-scores higher than -2
[23]. Moreover, their evolution can lead to changes in
treatment [116]. There are no studies that have defini-
tively determined how often VF should be monitored, al-
though some authors propose lateral spine x-rays on an
annual or biannual basis [23]. We propose their
frequency be individualized according to the patient’s
risk factors, with a minimum period of 6 months and a
maximum period of 2 years.
In addition, no studies or guidelines have established
the optimal periodicity for assessing phosphocalcic me-
tabolism. Our recommendation is to make an analytical
determination on an annual basis.
In regard to patients receiving calcium and vitamin D
supplementation, since the optimal intake for children
and adolescents suffering from chronic diseases is un-
known [41], doses should be modified according to cal-
ciuria and plasmatic levels of 25-hydroxyvitamin D3 and
iPTH. The optimal frequency for monitoring these param-
eters is unknown [49], although some authors advocate
that determinations should be made every 3–12months
[49, 51]. Our working group recommends that levels of
25-hydroxyvitamin D3 should be determined every 6–12
months, or after 3–6 months after a dose change. Further-
more, an annual determination of calciuria is recom-
mended. A renal ultrasound should be conducted to rule
out nephrocalcinosis in the event of calciuria increase, or
when urine collection is not possible.
Regarding children being treated with BPs, there are no
studies that have determined an optimal frequency for
analytical checks. Our group recommends monitorization
prior to each infusion for patients receiving intravenous
BPs, and every 6 months for patients taking BPs orally.
Corticosteroid-induced osteoporosis
GCs are widely used with a proven effectiveness in nu-
merous pediatric diseases. However, they carry multiple
side effects, and are associated with decreased BMD and
bone fragility fractures [118].
Patients treated with systemic GCs lose bone mass
more markedly during the first 3–6 months of treat-
ment, mainly trabecular bone [118]. This loss depends
on the dose and treatment duration [119, 120]. Although
lower doses are less harmful than higher doses, there ap-
pears to be no unequivocally safe dose since fracture risk
have been reported to persist with prednisone (or
equivalent) doses of 2. 5 a 7. 5 mg/ day [118].
Thus, as in other patients with osteoporosis risk fac-
tors, monitoring BMD and VF occurrence is advisable.
In the absence of clear data on the optimal time for a
DXA in this group, we recommend performing a DXA
during the first 6 months of treatment, and repeating it
every 9-12 months if treatment continues.
Regarding VF screening, some studies reported an in-
cidence rate of around 10% during the first year, with
nearly 50% of such cases being asymptomatic [70, 71].
For this reason, it is advisable to assess these patients
using imaging technique at the beginning of treatment,
and thereafter annually while GCs are maintained.
Table 6 Basic Diagnostic Studies
Laboratory test Variables to analyze
Blood count
Blood chemistry Calcium, ionized calcium, phosphorus,
magnesium, total proteins, creatinine, urea,
glucose, 25-hydroxyvitamin D3, PTH, TSH, free T4
24-hour urine
chemistry
Calcium, phosphorus, creatinine, tubular
phosphorus reabsorption, sodium
Urine screening Ca/Creatininea
Bone turnover
makers
Total alkaline phosphatase
aSample from a single urination, preferably first one in the morning
Table 7 Analytical determinations to make based on suspicion
Studies
1 Immunoglobulins
2 Anti-transglutaminase IgA antibodies
3 Cortisol
4 Prolactin
5 FSH, LH, testosterone
6 Homocysteine
7 Genetic studies (genes related to osteogenesis imperfecta
and disorders characterized by bone fragility)
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The Spanish Rheumatology Society Consensus [121]
holds that the prevention of GIOP must begin as early
as possible for all patients receiving doses higher than 5
mg/day of prednisone (or equivalent) for more than
three months. Preventive actions include prescribing the
lowest possible dose of GCs to control the underlying
disease, as well as encouraging physical exercise, avoid-
ing toxic products, such as tobacco and alcohol, and en-
suring a balanced diet with the required intake of
calcium and vitamin D [121]. In fact, a recent systemic
review concluded that calcium and vitamin D supple-
mentation should be started with the same dose recom-
mended for healthy children in all children on GCs,
particularly when treatment is expected to last more
than 3 months, as a preventive action against GIOP de-
velopment [95]. In addition, our group recommends
maintaining this supplementation for three months after
discontinuation of GCs treatment since its effect on
bone continues even after treatment has been halted.
Nevertheless, no studies have determined an optimal
period of supplementation. This same review recom-
mends the use of BPs for preventive purposes [95],
despite the lack of any comprehensive data. Our own
working group does not consider its systematic use in
the absence of fragility fractures. Nevertheless, its ef-
fectiveness is proven when GIOP has been estab-
lished; i.e., when pathological fractures are clearly
evident [87, 95, 96].
Most studies suggest that an inhaled GCs dose lower
than the equivalent of 800 mcg/day of budesonide has
only a minimum effect on fracture risk, while higher
doses are associated with an accelerated decrease in
BMD and a higher risk of fractures. In these patients, al-
though non-pharmacological preventive actions are jus-
tified [97, 98, 122], it is not advisable to routinely carry
out such procedures as lateral spine x-rays or DXAs,
unless these patients have other risk factors [97–99].
Furthermore, the role of calcium and vitamin D supple-
mentation in patients prescribed inhaled GCs has not
yet been established, although some groups recommend
supplementation for higher risk populations [93].
Conclusion
In summary, we present herein guidelines for the pre-
vention, diagnosis and treatment of secondary childhood
osteoporosis based on the available evidence and expert
clinical experience. We believe it can serve as a useful
tool that will contribute to the standardization of clinical
practice for this pathology. Prophylactic measures, early
diagnosis and a proper therapeutic approach are essen-
tial to improving bone health, not only in children and
adolescents, but also in the adults they will become in
the future.
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